pediatric leukemia at asco 2023
Published 1 year ago • 134 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:35
barriers that remain in the treatment of pediatric all with car-t therapies
-
1:36
insights into the biology of pediatric mds
-
2:14
top highlights from asco & eha 2023
-
1:23
azacitidine and venetoclax /- gemtuzumab ozogamicin in pediatric patients with r/r acute leukemias
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
4:41
acute myeloid leukemia survival rate and outlook
-
4:19
blinatumomab to achieve remission and consolidation with haplosct for pediatric all
-
0:46
an update on targeted therapy in pediatric leukemia
-
1:50
identifying new subtype-defining lesions in pediatric t-all
-
1:08
a phase ii study of ruxolitinib with chemotherapy in pediatric patients with ph-like all
-
1:45
impact of cytogenetic abnormalities on os following sct in pediatric aml
-
3:07
challenges and recent advances for pediatric all
-
1:49
asc4kids: investigating asciminib for pediatric patients with cml
-
2:13
the diagnosis and management of ta-tma in pediatric patients
-
1:04
phase i/ii study of bosutinib in newly diagnosed & resistant/intolerant pediatric patients with cml
-
1:32
trends in inpatient and icu resource utilization after car-t in pediatric all
-
1:04
scd highlights from eha 2023: the biology of pain crises & solace-kids
-
7:34
pediatric acute leukemia (pedal) screening trial: developing new therapies for relapsed leukemias
-
0:49
the future of pediatric clinical trials
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml